Impressive.
Negative: Despite moving things as fast as possible and working close with the FDA any results are probably at least a year away.
Positive: A registrational Ph1b and ODS could be on the cards plus the low sp valuing the company at almost NOTHING. But if approved then the sky could be the limit. If one has funds to take advantage of it, what an opportunity.
GLTA
Ann: Agreement with MD Anderson for Phase 1B CHM 0201 AML study, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |